Jeffrey A. Bogart,Xiaofei Wang,Gregory A. Masters,Junheng Gao,Ritsuko Komaki,Laurie E. Gaspar,John V. Heymach,James A. Bonner,Charles Kuzma,Saiama N. Waqar,W. Petty,Thomas E. Stinchcombe,Jeffrey D. Bradley,Everett E. Vokes
Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard for limited-stage small-cell lung cancer, most patients receive higher-dose once-daily regimens in clinical practice. Whether increasing radiotherapy dose improves outcomes remains to be prospectively demonstrated.